Global Metabolic Disorder Therapeutics Market to reach USD 98.52 billion by 2027.Global Metabolic Disorder Therapeutics Market is valued approximately USD 60.16 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 7.30% over the forecast period 2021-2027. Metabolic disorder occurs when abnormal chemical reactions in the body disrupt the process of making energy from the digested food. The rising awareness for the treatment of metabolic disorders and the new research and technological advancements are propelling the Metabolic Disorder Therapeutics market. The rising incidences of various metabolic disorders, especially obesity and diabetes, are also driving the Metabolic Disorder Therapeutics market. According to World Health Organization, an estimated 1.5 million deaths were directly caused by diabetes globally in 2019. Another 2.2 million deaths were attributable to high blood glucose in 2012. In 2019, International Diabetes Federation reports that approximately 463 million adults (20-79 years) were living with diabetes which will rise to 700 million in 2045. Proportion of people with type 2 diabetes is increasing in most countries, with 79% of adults with diabetes living in low- and middle-income countries. More than 1.1 million children and adolescents are living with type 1 diabetes worldwide. The expensive nature of some therapies for rare diseases as well as lack of unequivocal regulatory policies may act as a restraint for its growth. However, increasing awareness for harmful effects of obesity and importance of good metabolism after COVID-19 pandemic acts as an opportunity for Metabolic Disorder Therapeutics Market in subsequent decade.

Key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World are analysed to provide a holistic picture of Metabolic Disorder Therapeutics Market. Due to higher expenditure on healthcare as well as higher per capita income, North America has emerged as the significant region across the world in terms of market share. Whereas, Asia-Pacific is expected to exhibit the highest growth rate for the forecast period 2021-2027 owing to the rising disposable income and growing incidences of diabetes and obesity along with other metabolic disorders in the region.

Major market player included in this report are:
Novo Nordisk
Eli Lilly and Company
Shire Plc
Sanofi
Merck KGaA
AstraZeneca
AbbVie Inc.,
Actelion Pharmaceuticals Ltd
Amgen Inc.,
Biocon

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Disease:
Lysosomal Storage Diseases
Diabetes
Obesity
Inherited Metabolic Disorders
Hypercholesterolemia

By Route of Administration:
Oral Administration
Parenteral Administration
Other route of administration

By Therapy Type:
Enzyme Replacement Therapy
Cellular Transplantation
Small Molecule-Based Therapy
Substrate Reduction Therapy
Gene Therapy
Drug Therapy

By Region:
North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027

Target Audience of the Global Metabolic Disorder Therapeutics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors